Amazon's Cash Flow Squeeze Masks a Dual-Pronged Growth Engine

Despite a cash flow squeeze from massive investments, Amazon's AI services and new health delivery partnership with Eli Lilly are generating billions, justifying its aggressive expansion.

Amazon's aggressive capital expenditure plans, projected to reach a staggering $200 billion in 2026, are putting significant pressure on its financials. The company's free cash flow plummeted to $11 billion in 2025 from $38 billion the previous year, a direct result of a $50.7 billion surge in capital investments. Yet, beneath this cash-intensive expansion, two distinct and highly profitable engines are roaring to life, offering a clear path to justifying the massive outlay.

The first is a strategic foray into a booming consumer health market. In a move that leverages its core logistics supremacy, Amazon has partnered with pharmaceutical giant Eli Lilly. Since last Thursday, the e-commerce titan has been offering same-day delivery of the new GLP-1 weight-loss drug "Foundayo" to approximately half of its US customer base already connected to its rapid-delivery network. The company is further exploring the installation of automated dispensing kiosks in select clinics, signaling a deeper push into high-margin medical distribution.

Simultaneously, Amazon's internal technological bets are yielding financial results that have stunned observers. In his annual shareholder letter, CEO Andy Jassy revealed that the company's AI services within AWS now generate over $15 billion in annual revenue. More impressively, the homegrown chip business, featuring Graviton and Trainium processors, has scaled to an annual run rate exceeding $20 billion. Demand is so intense that the Trainium2 chips are sold out, and the upcoming Trainium3 generation is nearly fully pre-sold ahead of its series launch.

Jassy framed this growth with a striking historical parallel. He noted that AWS achieved $58 million in revenue three years after its launch, which was considered a success. The current AI services business is roughly 260 times larger at the same stage of development. Looking ahead, the CEO sees potential for the chip division to reach up to $50 billion in revenue, especially if Amazon moves forward with plans to sell entire chip racks to external customers—a move that would place it in direct competition with established semiconductor manufacturers.

The capital required to fuel this ambition is monumental. A significant portion is earmarked for data center infrastructure, including a newly announced $25 billion investment in Mississippi. Of that sum, $13 billion is allocated for a single facility in Madison County, a project state officials have dubbed the "Digital Delta," expected to create 2,000 high-skilled jobs.

Investors have responded positively to the long-term strategy despite the near-term cash flow contraction. The stock rallied 11.5% over the past week, with a notable 5.6% gain on Friday alone accompanied by trading volume roughly 30% above the three-month average. For the first quarter of 2026, Amazon projects net sales between $173.5 billion and $178.5 billion, representing growth of 11% to 15% year-over-year.

Wall Street analysts are adjusting their models to account for these new revenue streams. Jefferies maintains a price target of $300, citing the rapid monetization of AI infrastructure and the strategic pharmacy expansion as key levers. Cantor Fitzgerald raised its target from $250 to $260, reaffirming an "Overweight" rating. With an RSI hovering near 85, the stock is considered technically overbought in the short term, yet it still trades about 8% below its all-time high from last November. The company's challenge now is to continue scaling its dual growth engines fast enough to outpace its own immense spending.